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1. Introduction 
Pharmacogenomics is an evolving research discipline in medicine. Within ophthalmology, 
the earliest candidate gene investigations have studied primary and secondary open-angle 
glaucoma (OAG), as well as normal tension glaucoma (NTG). At this time, 
pharmacogenomics data are not generally used to make clinical decisions. However, as we 
collect data from clinical trials, the role of pharmacogenomics in the care of patients with 
glaucoma and allied diseases will become clearer. 
There are at least two potential future roles for applying pharmacogenomics in the treatment 
of OAG and allied disorders. First, more targeted therapy may lead to better treatment 
outcomes, with less exposure to medications in patients unlikely to respond to them. Second, 
pharmacogenomic research may lead to the development of novel therapies for these diseases. 
2. Pharmacogenomics of open-angle glaucoma 
Data from multiple randomized clinical trials (RCTs) have demonstrated that control of 
intraocular pressure (IOP) is generally effective in delaying progression of optic neuropathy 
and visual loss in patients with OAG, NTG, and ocular hypertension (OH) (Vass et al., 
2007). At present, two major categories of medications used to treat these disorders include 
ǃ-adrenergic antagonists and prostaglandin analogs. Unfortunately, both classes of 
medications are associated with a number of patients who are nonresponders. For example, 
a secondary analysis of pooled data from phase 3 RCTs reported a nonresponse rate of 28% 
with the ǃ-blocker timolol maleate and 18% with the prostaglandin analog latanoprost 
(Camras and Hedman, 2003). 
Using current clinical examination techniques, there is no reliable way to differentiate 
responders from nonresponders prior to initiation of therapy. Unfortunately, this “trial and 
error” strategy leads to, in at least some patients, extra office visits and exposure to additional 
medications. The precise mechanisms of nonresponsiveness remain poorly understood, but a 
genetic component is suspected. It is hoped that pharmacogenomics may lead to earlier 
identification of nonresponders and more targeted treatment decisions (Moroi et al., 2009). 
At this time, genotype-phenotype correlations have been studied, primarily using a candidate 
gene approach, with both ǃ-adrenergic antagonists and prostaglandin analogs. In addition, 
corticosteroid treatments are frequently associated with secondary elevated IOP, and the 
pharmacogenomics of the steroid response have also been studied (Schwartz et al., 2008). 
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2.1 β-adrenergic antagonists 
There is a growing body of literature regarding the pharmacogenomics of ophthalmic ǃ-
adrenergic antagonists, although at this time there is a lack of consensus regarding clinically 
significant genotype-phenotype associations. The ǃ-adrenergic antagonists include several 
non-selective agents (ǃ1- and ǃ2-antagonists), including timolol, and one ǃ1-selective 
antagonist, betaxolol. The non-selective agents are generally more effective and are therefore 
prescribed more frequently in the US (Allen et al., 1986). Betaxolol is associated with a high 
interpatient variability in response, which appears similar to the high interpatient variability 
in response associated with the use of systemic ǃ1-antagonists used in the treatment of 
systemic hypertension (Materson et al., 1993). 
The ǃ1-adrenergic receptor gene contains two well-characterized single nucleotide 
polymorphisms (Maqbool et al., 1999). At nucleotide 145, an A→G exchange causes a 
serine→glycine (Ser→Gly) substitution at codon 49 (Levin et al., 2002). Gly49 is found in 
about 14% of both Caucasians and African Americans (Moore et al., 1999). At nucleotide 
1165, a C→G exchange causes an arginine→glycine (Arg→Gly) substitution at codon 389 
(Mason et al., 1999). Gly389 is found in 42% of African Americans, but only 27% of 
Caucasians (Moore et al., 1999). 
In a prospective, nonrandomized clinical trial, 48 consecutive normal volunteers were treated 
with betaxolol for 6 weeks. The Arg389 homozygote genotype was associated with a 
significantly higher baseline IOP and a significantly greater magnitude of response to 
betaxolol therapy. Using multivariable linear regression, the Arg389 homozygote genotype 
was independently associated with a higher baseline IOP and a greater magnitude of response 
to betaxolol therapy, even after adjusting for baseline IOP. There were no statistically 
significant associations found with respect to the polymorphisms at codon 49 (Schwartz et al., 
2005). In a prospective study of 19 glaucoma patients and 18 normal volunteers treated with 
timolol, Ser49 homozygotes manifested lower heart rate, higher systolic arterial pressure, and 
higher diastolic arterial pressure than Gly49 carriers under the conditions evaluated 
(Nieminen et al., 2005). A Japanese study of 211 OAG patients, 294 patients with  NTG, and 
240 controls reported a significant association between NTG and the Arg389Gly 
polymorphism (Inagaki et al., 2006). 
The ǃ2-adrenergic receptor gene contains four well-characterized single nucleotide 
polymorphisms (Liggett, 2000). At nucleotide –47, a T→C exchange causes a 
cysteine→arginine (Cys→Arg) substitution at codon 19 (Parola and Kobilka, 1994). At 
nucleotide 46, a G→A exchange causes a glycine→arginine (Gly→Arg) substitution at codon 
16 (Green et al., 1993). At nucleotide 79, a C→G exchange causes a glutamine→glutamic acid 
(Gln→Glu) substitution at codon 27 (Green et al., 1994). At nucleotide 491, a C→T exchange 
causes a threonine→isoleucine (Thr→Ile) substitution at codon 164 (Green et al., 1993). 
The Personalized Medicine Research Project studied 210 patients in the United States being 
treated with topical ǃ-blockers. In these patients, Gln27 homozygotes were significantly 
more likely to experience a 20% or greater decrease in IOP following treatment, after 
adjusting for sex, family history of glaucoma, and use of systemic ǃ-blockers (McCarty et al., 
2008). However, other studies reported no significant associations between ǃ2-adrenergic 
receptor polymorphisms and clinical efficacy. In a prospective study of 89 normal 
volunteers treated with timolol, no association was found between the efficacy of timolol 
and the Arg16/Gln27, Gly16/Gln27, and Gly16/Glu27 variants (Fuchsjager-Maryl et al., 
2005). In an association study with 299 OAG patients and 284 controls, no differences in ǃ2-
adrenergic receptor gene alleles and haplotypes were found (McLaren et al., 2007). 
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The clinical efficacy of topical ǃ-blockers may be affected by other genes. For example, 
timolol is metabolized by cytochrome P40 2D6 (CYP2D6). Polymorphisms in this gene are 
associated with reduced efficacy of oral timolol in patients with systemic hypertension 
(McGourty et al., 1985). In a series of 19 OAG patients and 18 volunteers, poor metabolizers 
of CYP2D6 demonstrated higher systemic concentrations of ophthalmic timolol, suggesting 
a potential safety concern in these patients (Nieminen et al., 2005). In a series of 133 OAG 
patients, systemic bradycardia following administration of topical timolol was significantly 
associated with the genotype at the CYP2D6 Arg296Cys polymorphism (Yang et al., 2009). 
2.2 Prostaglandin analogs 
Latanoprost is a highly selective agonist of the prostaglandin F2ǂ (FP) receptor (Stjernschantz 
et al., 1995). The FP receptor gene, located on chromosome 1p31.1, belongs to the family of G 
protein coupled receptors (Betz et al., 1999).  
In a prospective, nonrandomized clinical trial, 100 normal volunteers were treated with 
latanoprost for 1 week. Ten polymorphisms in the FP receptor gene, of which 2 were novel, 
were studied. The polymorphisms rs3753380 and rs3766355 showed statistically significant 
associations with the magnitude of response to latanoprost. The promoter assay revealed 
that the C allele of rs3766355 and T allele of rs3753380 were associated with lower 
transcriptional activity of the FP receptor gene, which was in agreement with the differences 
of IOP response to latanoprost based on genotypes of these polymorphisms (Sakurai et al., 
2007). Using pathway analysis, the following polymorphisms were studied and found to 
have no statistically significant relationship with IOP reduction: T396A in prostaglandin 
transporter (Van Der Zwaag et al., 2002), P129T in fatty acid amide hydrolase (Sipe et al., 
2002), -1607 insG in MMP-1 gene (Rutter et al., 2002), C-1306T in MMP-2 gene (Price et al., 
2001), -1171 delA in MMP-3 gene (Ye et al., 1995), and C-1562T (Zhang et al., 1999) and CA 
repeats (-131~-90) in MMP-9 gene (St. Jean et al., 1995). 
2.3 Corticosteroid-induced glaucoma 
Some patients develop increased IOP and secondary OAG when exposed to corticosteroids. 
The etiology of this steroid response has never been fully explained, although a genetic 
determinant has been suspected for decades (Becker, 1965). Glucocorticoid receptors are 
present on the surface of trabecular meshwork cells, providing a possible mechanism for 
corticosteroid action on IOP (Weinreb et al., 1981). There are 6 well-known polymorphisms 
in the human glucocorticoid receptor gene (Tissing et al., 2005):  
1. ER22/23EK, a GAGAGG→GAAAAG substitution, which results in a GluArg→GluLys 
(ER→EK) substitution at codons 22-23 (van Rossum et al., 2002); 
2. N363S, an AAT→AGT substitution, which results in an Asn→Ser (N→S) substitution at 
codon 363 (Huizenga et al., 1998); 
3. BclI, a C→G substitution in intron 2 (van Rossum et al., 2003); 
4. N766N, an AAT→AAC substitution, which results in an Asn→Asn substitution (N→N) 
at codon 766 (Koper et al, 1997); 
5. a G→C substitution within intron 3 (Koper et al., 1997); 
6. a G→T substitution within intron 4. (Koper et al., 1997). 
In a study of 102 patients treated with topical corticosteroids following photorefractive 
keratectomy, N363S heterozygotes were associated with an increased risk of elevated IOP 
following treatment with topical prednisolone acetate (Szabo et al., 2007). 
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Intravitreal triamcinolone acetonide (IVTA) is used as an off-label treatment of several retinal 
diseases. Clinically significant IOP elevation has been reported in about 40% of these patients 
(Smithen et al., 2004). In a pilot study of 52 patients (56 eyes) treated with IVTA for various 
retinal diseases, no statistically significant associations were detected between any of the 6 
studied polymorphisms and IOP response following treatment (Gerzenstein et al., 2008). 
Other genes have been investigated for associations with the steroid response. The 
glucocorticoid receptor has multiple isoforms (Duma et al., 2006), and the expression of 
these isoforms is affected by the splicesome proteins SFRS9 (Xu et al., 2003) and SFRS5 (Yan 
et al., 2010), the immunophilins FKBP4 and FKBP5 (Zhang et al., 2008), and other proteins. 
In a series of 197 OAG patients, 107 steroid responders, and 400 controls, there were no 
statistically significant differences among the groups with respect to 48 polymorphisms in 
SFRS3, SFRS5, SFRS9, FKBP4, and the glucocorticoid receptor genes (Fingert et al., 2010). 
2.4 Pitfalls in applying pharmacogenomics to glaucoma research 
In pharmacogenomics, a positive result in one study may not be shown consistently in other 
studies. There are two main reasons for this discrepancy. First, different study populations 
may have very different baseline genetic characteristics. Second, other factors may influence 
drug efficacy in glaucoma patients. 
2.4.1 Differences in study populations 
Different study populations may have very different genetic characteristics. A 
polymorphism which is associated with nonresponsiveness to a certain medication may be 
insignificant in another study population because of the differences in the genetic 
backgrounds of subjects, or the polymorphism may not be informative due to a low minor 
allele frequency, or the population may be out of Hardy-Weinberg equilibrium. Therefore, 
interpretation of conflicting results of similar studies should be done with attention to the 
nature of the study populations. 
2.4.2 Factors influencing drug efficacy  
Other factors may influence drug efficacy in glaucoma patients. IOP fluctuation makes 
evaluation of IOP response problematic, because an IOP change involves both true 
pharmacological effect and spontaneous IOP fluctuations such as diurnal or day-to-day 
fluctuations. In addition, measurement errors in IOP are not negligible, especially when the 
magnitude of IOP reduction is small. Therefore, precise determination of drug efficacy is a 
key issue in pharmacogenomic studies of glaucoma. 
2.4.2.1 Baseline IOP 
Greater IOP reductions from topical medications have been reported to be associated with 
higher baseline IOP. For example, two studies examined the efficacy of latanoprost in 
patients with NTG (Rulo et al., 1996; Ang et al., 2004). Both studies showed that IOP 
reduction by latanoprost correlated significantly with baseline IOP. 
Currently, determinants of baseline IOP level in healthy subjects or in patients with NTG are 
largely unknown. Given that IOP fluctuates following a circadian rhythm, which is similar 
to the change in the activity of the sympathetic nervous system, the relationship between 
polymorphisms in adrenergic receptor genes and baseline IOP level was examined in two 
studies. In a US-based study of racially diverse patients, baseline IOP in normal subjects was 
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reported to be significantly higher in Arg389 homozygotes of the ǃ1-adrenergic receptor 
gene than in Gly389 carriers (Schwartz et al., 2005). In contrast, a study of untreated 
Japanese NTG patients reported that diurnal mean IOP was significantly higher for Ser49 
homozygotes in the ǃ1-adrenergic receptor gene than for Gly49 carriers, while the 
polymorphism at codon 389 was unrelated to the diurnal IOP level (Gao et al., 2010). In 
addition, two other polymorphisms, del 301-303 in ǂ2B-adrenergic receptor gene and del 
322-325 in the ǂ2C-adrenergic receptor gene, were associated with the difference in diurnal 
IOP level. The conflicting results between the two studies regarding the SNP at codon 389 in 
the ǃ1-adrenergic receptor gene may be attributed to different study populations, or to 
discrepancies between normal volunteers and untreated NTG patients, or to other factors. 
2.4.2.2 Central corneal thickness 
A thinner central cornea is a risk factor for the development of OAG, as reported by large-
scale clinical studies including the Barbados Incidence Study of Eye Diseases (Leske et al., 
2008) and the Ocular Hypertension Treatment Study (OHTS) (Gordon et al., 2002). 
Furthermore, in OHTS participants, thicker corneas were associated with smaller IOP 
responses to ǃ-adrenergic antagonists and prostaglandin analogues than normal or thin 
corneas (Brandt et al, 2004). These findings were not explained by an applanation artifact 
from a thin cornea. 
2.4.2.3 Race 
Significant associations have been reported between race and drug efficacy of ǃ-adrenergic 
antagonists and prostaglandin analogs. Timolol has been reported to be less effective in 
black patients with glaucoma or OH than in nonblacks (Higginbotham et al., 2002). 
Travoprost was reported to be more effective, while timolol was reported to be less effective, 
in black patients with OAG or OH than in nonblack patients (Netland et al., 2003). However, 
other studies have reported no association between race and drug efficacy. For example, an 
analysis of OHTS participants reported no statistically significant differences in IOP 
response to nonselective ǃ-adrenergic antagonists or prostaglandin analogs between self-
identified African American and Caucasian individuals (Mansberger et al., 2007). 
2.4.2.4 Other factors influencing evaluation of drug efficacy 
A number of other factors, including IOP fluctuations, errors in IOP measurements, and 
differences in medication compliance may modify the post-treatment IOP value and make 
the true IOP response difficult to measure. Furthermore, the true IOP response may vary 
over time (Takahashi et al., 2008). A one-eye trial of glaucoma medication, where the 
untreated eye serves as a control to subtract the IOP fluctuations, has been advocated to 
assess the true IOP responses (Shields, 1998). However, clinical usefulness of the one-eye 
trial has been questioned by several reports due to asymmetrical IOP fluctuations, especially 
in glaucoma patients (Chaudhary et al., 2008; Realini, 2009). Also, a one-eye trial is not 
suitable for drugs with contralateral effects, such as ǃ-adrenergic antagonists. Therefore, 
IOP measurements at several time points before and after treatments are thought to be 
necessary to estimate the average of the true IOP responses for each patient.  
3. Conclusions 
There is some clinical evidence that polymorphisms in the ǃ1-adrenergic receptor gene and 
the FP receptor gene affect clinical response to, respectively, betaxolol and latanoprost in 
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normal volunteers. The preliminary results with respect to betaxolol and latanoprost should 
be confirmed in patients with OH or OAG. The relationship between polymorphisms in the 
ǃ1-adrenergic receptor gene and clinical response to nonselective ǃ-blockers, such as 
timolol, is as yet not fully determined.  
At this time, there is no convincing evidence of any pharmacogenomic relationship with 
respect to steroid-induced glaucoma following treatment with IVTA. However, these early 
findings are noteworthy and merit further investigation. Any potential pharmacogenomic 
association with steroid response might lead to a molecular drug target for future therapy of 
steroid-induced glaucoma, as well as a better understanding of the steroid response. 
Despite the recent advances in ophthalmic pharmacogenomics, there is still much that 
remains to be elucidated. For example, to our knowledge, there are currently no peer-
reviewed data regarding possible pharmacogenomic relationships affecting other 
medications used in the treatment of glaucoma, such as carbonic anhydrase inhibitors, ǂ1-
agonists, and cholinergic agents. 
Even within the systems described here, there are many additional candidate genes and 
pathways for future association studies. Both the ǃ-adrenergic receptor and the FP receptor 
pathways utilize a second messenger system, interacting with a G-protein, a primary 
effector, a secondary messenger, and secondary effectors. Elements of these pathways, as 
well as their regulatory components, are reasonable candidates for future analysis.  
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